<?xml version="1.0" encoding="UTF-8"?>
<p id="Par15">The clinical trial is conducted in accordance with 
 <italic>The World Medical Association-Declaration of Helsinki</italic> and the guidelines of Criteria for the Quality Control of Clinical Trial of Drugs promulgated by the CDE. This prospective phase III clinical trial explores the efficacy and safety of nab-paclitaxel (keailiÂ®, CSPC Ouyi Pharmaceutical Co. Ltd.) combined with S-1 vs. oxaliplatin combined with capecitabine in the treatment of stage III gastric cancer. The trial protocol has been approved by the Review Board (IRB) of each participating institution and by the Cancer Hospital Affiliated to the Chinese Academy of Sciences. The protocol of this study has been registered in the ClinicalTrials.gov registry (NCT04135781; October 20th, 2019).
</p>
